Tylenol Maker Kenvue Rebounds In Premarket After Trump Links Drug To Autism
1. Kenvue shares rose 6.7% following Donald Trump's controversial claims. 2. The company disputed Trump's statements, citing scientific evidence against them. 3. Analysts see limited judicial risk despite potential impact on public perception. 4. 23% of U.S. adults use acetaminophen weekly, indicating significant market presence. 5. Recent studies show no link between acetaminophen and autism risk.